The association of dental plaque with cancer mortality in Sweden. A longitudinal study

Birgitta Söder,1 Maha Yakob,1 Jukka H Meurman,2 Leif C Andersson,3 Per-Östen Söder1

ABSTRACT

Objectives: To study whether the amount of dental plaque, which indicates poor oral hygiene and is potential source of oral infections, associates with premature death from cancer.

Design: Prospective cohort study.

Participants: 1390 randomly selected healthy young Swedes followed up from 1985 to 2009. All subjects underwent oral clinical examination and answered a questionnaire assessing background variables such as socioeconomic status and smoking.

Outcome measures: Causes of death were recorded from national statistics and classified according to the WHO International Classification of Diseases. Unpaired t test, χ2 tests and multiple logistic regressions were used.

Results: Of the 1390 participants, 4.2% had died during the follow-up. Women had died at a mean age of 61.0 (±2.6 SD) years and men at the age of 60.2 (±2.9 SD) years. The amount of dental plaque between those who had died versus survived was statistically significant (p<0.001). In multiple logistic regression analysis, dental plaque appeared to be a significant independent predictor associated with 1.79 times the OR of death (p<0.05). Age increased the risk with an OR of 1.98 (p<0.05) and gender (men) with an OR of 1.91 (p<0.05). The malignancies were more widely scattered in men, while breast cancer was the most frequent cause of death in women.

Conclusions: This study hypothesis was confirmed by showing that poor oral hygiene, as reflected in the amount of dental plaque, was associated with increased cancer mortality.

INTRODUCTION

Dental plaque is a bacterial biofilm formed on dental surfaces. It plays a role in the aetiology of oral diseases such as caries and periodontal disease but may also associate with systemic health and diseases due to direct or hematogenic spread of microorganisms with subsequent upregulation of cytokines and inflammatory mediators.1 The dento-gingival region is a natural habitat for a magnitude of oral bacteria. The average total microscopic count of bacteria from the dental plaque has been calculated to be up to 2.1×109/mg wet weight.2 3 Paster et al4 estimated that there are 415 species of non-specific bacteria in the subgingival plaque, while pyro-sequencing techniques analysing dental plaque and saliva have shown that even thousands of microbial species may inhabit the oral cavity.5

Carcinogenesis is a multi-step process in which cells accumulate changes in their genetic material giving rise to alterations of function.6 These metabolic cascades can also be triggered by infection and inflammation which, in fact, have been estimated to play a role in 15%–20% of all malignancies.7 Because oral infections, and periodontitis in particular, are highly prevalent in populations, there has been interest in studying...
the eventual link between oral infections and the prevalence of cancer. Smoking is a common risk factor both for periodontitis and in many types of malignancies; thus, smoking needs always to be taken into account in this context. Our group published a study in 2007 showing that patients with periodontitis and missing molars seem to be at increased risk for premature death by life-threatening diseases, such as neoplasms and diseases of the circulatory and digestive systems.

We have recently also published a study showing an association between periodontal disease and breast cancer, with an OR of 2.36. The putative mechanisms involved in the association have been further reviewed by Meurman and Bascones-Martinez. Considering these observations, the hypothesis of the present study was that dental plaque is associated with premature death in cancer. A high amount of dental plaque indicates poor oral hygiene and, subsequently, was thought to be a surrogate for increased risk for dental infections. These, in turn, by triggering systemic reactions were thought to lead to malignant transformation in a variety of tissues. The specific aim of this study was to investigate the underlying causes of death in malignancies among 1390 randomly selected young Swedes who had been clinically investigated and followed up from 1985 to 2009. The Swedish national hospital admission and death registers were used to record cancer. Death from cancer was considered the end point of the study.

MATERIALS AND METHODS
Study population
In 1985, we undertook a study comprising a random sample of 3273 individuals aged 30–40 years. The subjects were selected from a registry file of all inhabitants of Stockholm County born on the 20th of any month from 1945 to 1954 (n=105 798). They were informed about the purpose of the study and offered a clinical oral examination. In total, 1676 individuals (51.2%), 838 men and 838 women, underwent the examination and answered a questionnaire. Of them, 286 had periodontal disease, while 1390 had no signs of periodontitis and were regarded as periodontally healthy. These 1390 subjects were then included in the present study. The study profile is given in figure 1.

The following oral health parameters were recorded for the 1390 individuals with no periodontal disease: the number of remaining teeth excluding third molars, gingival inflammation around every tooth using the gingival index and oral hygiene status using the plaque index (PLI) and the calculus index to assess all six surfaces of six representative teeth. Gingival crevices were measured using a periodontal probe and recorded to the nearest higher millimetre for six sites of each tooth. Presence or absence of each tooth was recorded. All subjects answered a questionnaire concerning topics such as regular dental visits and the use of tobacco. Smoking was expressed in pack-years of smoking in the analyses.

Socioeconomic and mortality data
The cumulated causes of death in the 1390 subjects followed up from 1985 to 2009 were obtained from the Centre of Epidemiology, Swedish National Board of Health and Welfare, Sweden. The data regarding the causes of death were classified according to the WHO International Statistical Classification of Diseases and Related Health Problems (ICD), ICD-7, ICD-9 and ICD-10, respectively. Socioeconomic data were obtained from the National Statistics Centre, Örebro, Sweden.

The Ethics Committee of the Karolinska Institute and Huddinge University Hospital, Sweden, had approved the study protocol (permit 2007/1669-31). The study is in accordance with the Declaration of Helsinki as revised in 1983.

Statistical analysis
Unpaired t test, $\chi^2$ tests, multiple regression analysis and multiple logistic regression analysis were applied when appropriate. We used multiple logistic regression
By the follow-up year of 2009, of the 1390 persons originally examined, 58 subjects had passed away, 35.6% of them were women and 64.4% were men. The difference between genders was statistically significant (p < 0.05). Of the total of 3273 participants in the original cohort, 6.21% had died: 2.3% of the women and 3.9% of the men (p < 0.01). Approximately 6.9% of the women and 4.0% of the men had died from different cancers by the year 2009 (p < 0.05). The women died at the average age of 61.0 (±2.67 SD) years and men at the average age of 60.2 (±2.96 SD) years. The difference between genders was not statistically significant.

Demographic and clinical oral health data at the 1985 baseline examination of the 1390 subjects who were dead or alive by the follow-up year of 2009

| Gender (female/male) | Dead (n = 58) | Alive (n = 1332) | p Value* |
|---------------------|-------------|-----------------|----------|
|                     | Number, mean ± SD | Number, mean ± SD |          |
| Gender (female/male) | 22/36       | 691/641         | <0.05    |
| Age in 1985 (years) | 36.5±2.9    | 35.5±2.8        | <0.05    |
| Education (compulsory school/higher) | 14/44 | 221/1111 | <0.001 |
| Smoking (pack-year) | 3090.7±3170.5 | 2113.0±2901.5  | <0.05 |
| Income (Swedish Crowns × 1000) | 200.5±126.1 | 180.0±99.7 | NS |
| Plaque index        | 0.87±0.62   | 0.67±0.46       | <0.001  |
| Gingival inflammation | 1.41±0.56  | 1.17±0.46       | <0.001  |
| Calculus index      | 0.57±0.68   | 0.38±0.51       | 0.008   |
| Missing teeth       | 1.64±2.90   | 1.17±2.34       | NS |
| Missing molars in the mandible | 0.74±1.34 | 0.47±1.17 | NS |

Data are expressed as mean ± SD.
*Fisher’s exact t test or Student’s t test for unpaired samples as appropriate.

RESULTS

By the follow-up year of 2009, of the 1390 persons originally examined, 58 subjects had passed away, 35.6% of them were women and 64.4% were men. The difference between genders was statistically significant (p = 0.01). Of the total of 3273 participants in the original cohort, 6.21% had died: 2.3% of the women and 3.9% of the men (p < 0.001). Approximately 6.9% of the women and 4.0% of the men had died from different cancers by the year 2009 (p < 0.05). The women died at the average age of 61.0 (±2.67 SD) years and men at the average age of 60.2 (±2.96 SD) years. The difference between genders was not statistically significant.

Demographic data and risk indicators at the baseline examination in 1985 are given in table 1. As mentioned previously, significantly more women than men were alive at the end of the study. The relative number of individuals with higher education was greater in the survivors, whereas higher pack-years of smoking characterised the persons who had passed away.

Statistically significant differences were evident between the groups regarding the amount of dental plaque, gingival inflammation and dental calculus, indicating a significantly poorer dental status in the subjects who died when compared with the survivors. The amount of dental plaque at the baseline examination in 1985, in subjects who were dead or alive in 2009, is given in table 2. Those who had died by the year 2009 had PLI values from 0.84 to 0.87 (as recorded in 1985), indicating that the gingival region of the teeth had been covered with dental plaque. Those who survived had, respectively, in 1985, had constantly lower mean values of dental plaque (PLI 0.66). Thus, their gingival region had been only partly covered with plaque. The differences between the groups increased significantly also when comparing the 1985 clinical recordings from 1996 to 2009, as also given in table 2.

In the multiple logistic regression analysis, age, male gender and the amount of dental plaque appeared to be the principal independent predictors for death during the follow-up as given in table 3. Dental plaque associated with 1.79 times the odds of premature death. Except for age, which associated 1.98 times the odds for
death, and male gender (OR 1.91), the other factors considered in the model exerted no significant independent influence on these three variables.

The causes of death due to malignancies are given in detail in Table 4. In the women, malignant neoplasm of the breast was the most frequent cause of death. In men, the diagnoses of malignancies were more widely scattered. In three cases, two women and one man, no cause or underlying cause of death could be found in the register file.

**DISCUSSION**

This study addressed the issue of dental plaque as a risk marker for mortality by evaluating the relationship between the clinically recorded amount of dental plaque and death due to malignancies 24 years after the baseline dental examination. Our results confirmed the study hypothesis by showing that the amount of dental plaque indeed associated with death in cancer, similar to what was observed with age and male gender. The deceased women in the study cohort were expected to live 13.1 years longer and the deceased men 8.6 years longer, according to population demographics in Sweden. Hence, the deaths recorded here could be termed ‘premature deaths’.

Regarding the reliability of the results, our subjects were randomly chosen to avoid selection bias. The large subject pool was representative of the ethnically homogenous Swedish adult population, with an age range of 10 years to limit the influence of age differences. The study had a longitudinal prospective design with a cohort of subjects whose oral health status was documented at the baseline 24 years earlier. The statistical analysis was performed with adjustments for several demographic variables and established risk markers for mortality, such as education, pack-years of smoking, frequency of dental visits, income level, socioeconomic status, gingival inflammation and periodontal disease. Therefore, none of these variables confounded the association observed between the age, male gender, the amount of dental plaque and premature death.

The subjects who had died by the year 2009 had been healthy in the 1985 examination, with no signs of periodontal or other oral disease; however, a voluminous oral biofilm had been covering the gingival crevice.

### Table 3

| Dependent variable | Explaining variable | $\beta$ | $\chi^2$ | p Value | OR (95% CI) |
|--------------------|---------------------|--------|---------|---------|-------------|
| Death              | Age                 | 0.68   | 5.27    | 0.022   | 1.98 (1.11 to 3.54) |
|                    | Gender (male)       | 0.65   | 4.50    | 0.034   | 1.91 (1.05 to 3.46) |
|                    | Dental plaque       | 0.58   | 3.90    | 0.048   | 1.79 (1.01 to 3.19) |

Cox & Snell $R^2 = 0.017$; Nagelkerke $R^2 = 0.060$.

### Table 4

| ICD-10                                           | Men (n) | Women (n) |
|--------------------------------------------------|---------|-----------|
| Malignant neoplasm of oesophagus, abdominal part of oesophagus (C15.2) | 1       | 1         |
| Malignant neoplasm of colon, sigmoid colon (C18.7)    |         |           |
| Malignant neoplasm of rectum, rectal ampulla (C20) | 1       |           |
| Malignant neoplasm of pancreas, unspecified (C25.9) | 1       | 2         |
| Malignant neoplasm of bronchus and lung, upper lobe, bronchus or lung (C34.1) | 1       |           |
| Malignant neoplasm of bronchus and lung, unspecified (C34.9) | 1       |           |
| Malignant melanoma of trunk (C43.5) | 2       |           |
| Malignant melanoma of lower limb, including hip (C43.7) | 1       |           |
| Malignant neoplasm of skin, skin of lower limb, including hip (C44.7) | 1       |           |
| Malignant neoplasm of connective and soft tissue of lower limb, including hip (C49.2) | 1       |           |
| Malignant neoplasm of breast, upper-outter quadrant of breast (C50.4) | 4       |           |
| Malignant neoplasm of breast, unspecified (C50.9) | 8       |           |
| Malignant neoplasm of cervix uteri (C53.9) | 1       |           |
| Malignant neoplasm of corpus uteri, endometrium (C54.1) | 1       |           |
| Malignant neoplasm of prostate (C61.9) | 2       |           |
| Malignant neoplasm of bladder, unspecified (C67.9) | 1       | 1         |
| Malignant neoplasm of eye (C69.9) | 1       | 1         |
| Malignant neoplasm of meninges, cerebral meninges (C70.0) | 1       |           |
| Malignant neoplasm of brain, temporal lobe (C71.2) | 1       |           |
| Malignant neoplasm, parathyroid gland (C75.0) | 1       |           |
| Malignant neoplasm, pituitary gland (C75.1) | 1       |           |
(table 2). According to Socransky and Haffajee, in healthy individuals, even with no signs of periodontal disease, the microbial plaque may still contain $33 \times 10^{18}$ cells. A healthy oral cavity harbours a characteristic bacterial flora that differs from that observed in oral disease states. The tooth surfaces are in contrast to the bacterial flora that differs from that observed in oral cavity bacteria. If maintaining daily oral hygiene is neglected, microbial deposits accumulate. Consequently, microbial cells, toxins, and enzymes are released from the biofilm and through the epithelium, particularly in the gingival crevice; the microbes and their metabolites may enter the blood circulation and spread to different parts of the body with potential systemic consequences.

In the year 2009, there were altogether 54,611 cases of cancer diagnosed and reported to the Swedish Cancer Registry (the gender distribution was 53% men and 47% women). During the last 2 decades, the average annual increase in the number of cases with malignancies has been 1.9% for men and 1.3% for women. These figures can be compared with those in the present cohort, where altogether 203 subjects had died from cancer: 6.9% women and 4.0% men. The increase in cancer cases can be partly explained by the ageing population and by the introduction of screening activities and improvements in diagnostic practices.

Breast cancer is the most common cancer in women in Sweden. It represented 29% of the cases reported to the Swedish National Cancer Registry in the year 2009. Breast cancer was the most common cancer causing death in women in the present study also, representing 21.4% (table 4). In men, in turn, the most frequent cancer in Europe is prostate cancer, with increasing incidence over the past 2 decades. The incidence of prostate cancer appears particularly high in Sweden, Finland and in The Netherlands. In Sweden, prostate cancer represented 36% of the male cases in 2009 in the national registry. In general, the increase in prostate cancer prevalence is related to the use of prostate-specific antigen in diagnosis, and therefore, it is uncertain how the incidence trend will develop over the coming years. In the present study, 3.6% of the men had died in prostate cancer.

In conclusion, based on the present findings, the high bacterial load on tooth surfaces and in gingival pockets over a prolonged time may indeed play a role in carcinogenesis. Therefore, the control of oral biofilm, in order to reduce the burden of the microbial noxa from the mouth, seems important to combat this development. Further studies are definitely required, however, to determine whether there is any causal element in the observed association reported here. If proven to be so, then new strategies for prevention and practical health recommendations would be warranted.

Contributors All authors fulfilled all three of the ICMJE guidelines for authorship that are (1) substantial contributions to conception and design, acquisition of data or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content and (3) final approval of the version to be published. Dr BS is the corresponding author. She had full access to all data in the study and had final decision to submit the manuscript for publication.

Funding This study was supported by Ministry of Health and Social Affairs (grants F84/189 and Karolinska Institutet, Stockholm, Sweden, The Finnish Medical Society, Helsinki, and by grant TI020Y0003 by the Helsinki University Central Hospital, Finland.

Competing interests None.

Patient consent Obtained.

Ethics approval Ethics approval was provided by the Ethics Committee of the Karolinska Institute and Huddinge University Hospital, Sweden, had approved the study protocol (permit 2007/1669-31). The study is in accordance with the Declaration of Helsinki as revised in 1983.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No unpublished data are available.

REFERENCES

1. Bascones-Martínez A, Muñoz-Corcuera M, Meurman JH. Odontogenic infections in the etiology of infective endocarditis. Cardiovasc Hematol Disord Drug Targets 2009;9:231–5.
2. Socransky SS, Gibbons RJ, Sawyer S, et al. The microbiota of the gingival crevice area of man. II. The predominant cultivable organisms. Arch Oral Biol 1963;8:281–9.
3. Socransky SS, Haffajee AD. Periodontal microbial ecology. Periodontal 2000 2000;5:38:135–87.
4. Paster BJ, Boches SK. Bacterial diversity in human subgingival plaque. J Bacteriol 2001;183:3770–83.
5. Keijser BJ, Zaura E, Huse SM, et al. Pyrosequencing analysis of the oral microbiota of healthy adults. J Dent Res 2008;87:1016–20.
6. Chang AH, Parsonnet J. Role of bacteria in oncogenesis. Clin Microbiol Rev 2010;23:502–57.
7. Allavena P, Garlanda C, Borrello MG, et al. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 2008;18:3–10.
8. Warnakulasuriya S. Living with oral cancer: epidemiology with particular reference to prevalence and life-style changes that influence survival. Oral Oncol 2010;46:407–10.
9. Söder B, Jin LJ, Klinge B, et al. Periodontitis and premature death: a 16-year longitudinal study in a Swedish urban population. J Periodontol 2007;82:461–6.
10. Söder B, Yakob M, Meurman JH, et al. Periodontal disease may associate with breast cancer. Breast Cancer Res Treat 2011;127:497–502.
11. Meurman JH, Bascones-Martínez A. Are oral and dental diseases linked to cancer? Oral Dis 2011;17:779–84.
12. Loe H, Theilade E, Jensen B. Experimental gingivitis in man. II. The predominant cultivable organisms. Acta Odontol Scand 1963;8:281.
13. Söder B, Jin LJ, Klinge B, et al. Periodontitis and premature death: a 16-year longitudinal study in a Swedish urban population. J Periodontol 2007;82:461–6.
14. Söder B, Meurman JH, et al. Periodontal disease may associate with breast cancer. Breast Cancer Res Treat 2011;127:497–502.
15. Meurman JH, Bascones-Martínez A. Are oral and dental diseases linked to cancer? Oral Dis 2011;17:779–84.
16. Loe H, Theilade E, Jensen B. Experimental gingivitis in man. J Periodontal 1965;36:177–87.
17. Sillness J, Loe H. Periodontal disease in Pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 1964;22:121–35.
18. Greene JC, Vermillion JG. The oral hygiene index: a method for classifying oral hygiene status. J Am Dent Assoc 1960;61:172–9.
19. Cancer Incidence in Sweden 2009. Vol. 52. Stockholm, Sweden: Swedish Cancer Registry, 2010:2–104.
20. Life Expectancy 1861-2009. Statistical Year-Book of Stockholm 2011. Vol. 104. Stockholm: Stockholm Office of Research and Statistics (USK).
21. Aas JA, Paster BJ, Stokes LN, et al. Defining the normal bacterial flora of the oral cavity. J Clin Microbiol 2005;43:5721–32.
22. Brat F, Lortel-Tielent J, Ferlay J, et al. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2008;46:3040–52.
### STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

| Section/Topic          | Item # | Recommendation                                                                 | Reported on page # |
|------------------------|--------|-------------------------------------------------------------------------------|--------------------|
| **Title and abstract** | 1      | (a) Indicate the study’s design with a commonly used term in the title or the abstract | 1,2                |
|                        |        | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 2                  |
| **Introduction**       | 2      | Explain the scientific background and rationale for the investigation being reported | 3,4                |
| **Objectives**         | 3      | State specific objectives, including any prespecified hypotheses                | 3,4                |
| **Methods**            |        |                                                                               |                    |
| Study design           | 4      | Present key elements of study design early in the paper                         | 4,5                |
| Setting                | 5      | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 4,5                |
| Participants           | 6      | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | 4,5                |
|                        |        | (b) For matched studies, give matching criteria and number of exposed and unexposed | -                  |
| Variables              | 7      | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 4,5                |
| Data sources/          | 8*     | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 4,5                |
| measurement**          |        |                                                                               |                    |
| Bias                   | 9      | Describe any efforts to address potential sources of bias                        | 4,5                |
| Study size             | 10     | Explain how the study size was arrived at                                       | 4,5                |
| Quantitative variables | 11     | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 4,5                |
| Statistical methods    | 12     | (a) Describe all statistical methods, including those used to control for confounding | 5                  |
|                        |        | (b) Describe any methods used to examine subgroups and interactions             | 5                  |
|                        |        | (c) Explain how missing data were addressed                                     | -                  |
|                        |        | (d) If applicable, explain how loss to follow-up was addressed                  | -                  |
|                        |        | (e) Describe any sensitivity analyses                                          | 5                  |
| **Results**            |        |                                                                               |                    |
| Section               | Items | Notes                                                                 |
|-----------------------|-------|----------------------------------------------------------------------|
| Participants          | 13*   | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 5 |
|                       |       | (b) Give reasons for non-participation at each stage                  |
|                       |       | (c) Consider use of a flow diagram                                     |
| Descriptive data      | 14*   | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders 5,6 |
|                       |       | (b) Indicate number of participants with missing data for each variable of interest |
|                       |       | (c) Summarise follow-up time (eg, average and total amount)           4-7 |
| Outcome data          | 15*   | Report numbers of outcome events or summary measures over time         5-8 |
| Main results          | 16    | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included 5-8 |
|                       |       | (b) Report category boundaries when continuous variables were categorized |
|                       |       | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period |
| Other analyses        | 17    | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses |
| Discussion            |       |                                                                      |
| Key results           | 18    | Summarise key results with reference to study objectives              9-10 |
| Limitations           |       |                                                                      |
| Interpretation        | 20    | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence 9-10 |
| Generalisability      | 21    | Discuss the generalisability (external validity) of the study results 9-10 |
| Other information     |       |                                                                      |
| Funding               | 22    | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based 10 |

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.